The role of cyclooxygenase in carcinogenesis and anticancer therapy

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 27, Issue 8, 2005, Pages 616-627

  Flory, Andrea B ^a   LeBlanc, Amy K ^b  

^a Department of Obstetrics Gynecology   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 24644508504     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Jelinek F: Postinflammatory sarcoma in cats. Exp Toxicol Pathol 55(2-3): 167-172, 2003.
2. Knecht CD: Osteosarcoma in dogs: A study of previous trauma, fracture, and fracture fixation. JAAHA 14:82-84, 2004.
3. London CA, Dubilzeig RR, Vail DM, et al: Evaluation of dogs and cats with tumors of the ear canal: 145 cases (1978-1992). JAVMA 208(9):1413-1418, 1996.
4. Baskin CR, Couto CG, Wittum TE: Factors influencing first remission and survival in 145 dogs with lymphoma: A retrospective study. JAAHA 36(5): 404-409, 2000.
5. de Mello Souza CH, et al: Nonsteroidal anti-inflammatory drugs (NSAIDs) and cancer: Chemoprevention and treatment. Vet Cancer Soc News 8-10, 2004.
6. Knapp DW, Chan TC, Kuczek T, et al: Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am J Vet Res 56(6):801-805, 1995.
7. Jones CJ, Budsberg SC: Physiologic characteristics and clinical importance of the cyclooxygenase isoforms in dogs and cats. JAVMA 217(5):721-729, 2000.
8. Tomlinson J, Blikslager A: Role of nonsteroidal anti-inflammatory drugs in gastrointestinal tract injury and repair. JAVMA 222(7):946-951, 2003.
9. Williams CS, Mann M, DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18(55):7908-7916, 1999.
10. Fossilen E: Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 37(5):431-502, 2000.
11. Mohammed SI, Khan KN, Sellers RS, et al: Expression of cyclooxygenase-1 and 2 in naturally occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 70(5):479-483, 2004.
12. 2 concentrations in naturally occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 64(1):1-4, 2001.
13. Borzacchiello G, Paciello O, Papparella S: Expression of cyclooxygenase-1 and -2 in canine nasal carcinomas. J Comp Pathol 131(1):70-76,2004.
14. Khan KN, Knapp DW, DeNicola DB, Harris RK: Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 61(5):478-481, 2000.
15. Mohammed SI, Bennett PF, Craig BA, et al: Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 62(2): 356-358, 2002.
16. Tremblay C, Dore M, Bochsler PN, Sirois J: Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma. J Natl Cancer Inst 91(16):1398-1403, 1999.
17. Pestili de Almeida EM, Piche C, Sirois J, Dore M: Expression of cyclo-oxygenase-2 in naturally occurring squamous cell carcinomas in dogs. J Histochem Cytochem 49(7):867-875, 2001.
18. McEntee MF, Cates JM, Neilsen N: Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs. Vet Pathol 39(4):428-436, 2002.
19. Dore M, Lanthier I, Sirois J: Cyclooxygenase-2 expression in canine mammary tumors. Vet Pathol 40(2):207-212, 2003.
20. Khan KN, Stanfield KM, Trajkovic D, Knapp DW: Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol 38(1):116-119, 2001.
21. Kleiter M, Malarkey DE, Ruslander DE, Thrall DEL: Expression of cyclooxygenase-2 in canine epithelial nasal tumors. Vet Radiol Ultrasound 45(3): 255-260, 2004.
22. Greenberg CB, Snyder PW, Khan KN, et al: Cyclooxygenase-2 expression in naturally occurring canine osteosarcoma: A preliminary report. Vet Cancer Soc Proc:11, 2003.
23. Mullins MN, Ehrhart EJ, Lana SE, et al: Cyclooxygenase-2 expression in canine appendicular osteosarcomas. Vet Cancer Soc Proc.15, 2003.
24. Knapp DW, Richardson RC, Chan TC, et al: Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 8(4): 273-278, 1994.
25. Mohammed SI, Craig BA, Mutsaers AJ, et al: Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther 2(2):183-188, 2003.
26. Beam SL, Rassnick KM, Moore AS, McDonough SP: An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms. Vet Pathol 40(5):496-500, 2003.
27. Wilson JE, Chandrasekharan NV, Westover KD, et al: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res 65(6):810-818, 2004.
28. Williams CS, Watson AJ, Sheng H, et al: Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models. Cancer Res 60(21):6045-6051, 2000.
29. Knapp DW, Richardson RC, Bottoms GD, et al: Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 29(3):214-218, 1992.
30. Norris AM, Laing EJ, Valli VE, et al: Canine bladder and urethral tumors: A retrospective study of 115 cases (1980-1985). J Vet Intern Med 6(3):145-153, 1992.
31. Henry CJ, McCaw DL, Turnquist SE, et al: Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res 9(2):906-911, 2003.
32. Poirier VJ, Forrest LJ, Adams WM, Vail DM: Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: A pilot study. JAAHA 40(2):131-136, 2004.
33. Knapp DW, Glickman NW, Widmer WR, et al: Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 46(3):221-226, 2000.
34. Boria PA, Murry DJ, Bennett PF, et al: Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. JAVMA 224(3):388-394, 2004.
35. Boria PA, Biolsi SA, Greenberg CB, et al: Preliminary evaluation of deracoxib in canine transitional cell carcinoma of the urinary bladder. Vet Cancer Soc Proc:17, 2003.
36. Schmidt BR, Glickman NW, DeNicola DB, et al: Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. JAVMA 218(11): 1783-1786, 2001.
37. Knottenbelt CM, Simpson JW, Tasker S, et al: Preliminary clinical observations on the use of piroxicam in the management of rectal tubulopapillary polyps. J Small Anim Pract 41(9):393-397, 2000.
38. Knottenbelt CM, Simpson JW, Chandler ML: Neutrophilic leucocytosis in a dog with a rectal tumour. J Small Anim Pract 41(10):457-460, 2000.
39. Sorenmo KU, Goldschmidt MH, Hofer FS, et al: Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet Comp Oncol 2(1):13-23, 2004.
40. Mutsaers AJ, Glickman NW, DeNicola DB, et al: Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs. JAVMA 220(12):1813-1817, 2002.